Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
BMY(NYSE:BMY) PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
BMY(NYSE:BMY) PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology Congress 2025
Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
BMY(NYSE:BMY) PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. The company will take part in a fireside chat beginning at 8:30 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Tr
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
BMYPRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMYPRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb’s Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Bristol Myers Squibb Announces Dividend
BMYPRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
BMYPRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #18ICML--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BMYBioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.
Bristol Myers Squibb Presents Updated Clinical Findings On CELMoD Agents Mezigdomide And Iberdomide In Multiple Myeloma, Golcadomide In Non-Hodgkin Lymphoma, And First Results Evaluating Oral BCL6 LDD In Non-Hodgkin Lymphoma, At EHA 2025
BMYBristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
BMYPRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
BMYPRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
BMYPRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
BMYPRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
Bristol Myers Squibb Announces Phase 3 POETYK PsA-1 Trial Met Primary Endpoint For Sotyktu In Psoriatic Arthritis
BMYBristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMYPRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EULAR--BMS Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu...
Reported Earlier, Philochem Licenses Global Rights To Prostate Cancer Radiopharmaceutical OncoACP3 To RayzeBio, A Bristol-Myers Squibb Company, In Deal Worth Up To $1.35B
BMYBristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug
BMYBioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion.
BioNTech And Bristol Myers Squibb Partner To Advance Bispecific Antibody BNT327 For Solid Tumors
BMYBristol Myers Squibb Gets EU OK for First-of-Its-Kind 5-Minute Injection Cancer Drug Opdivo SC
BMYBristol Myers Squibb To Present Data Highlighting Differentiated Research Platform Of Oncology Treatments And Innovative Research Pipeline At ASCO 2025
BMYOptions Corner: Political Turmoil Sets Up A Contrarian Call Spread For Bristol-Myers Squibb
BMYAlthough the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock.
Bristol Myers Squibb Receives European Commission Approval For Perioperative Regimen Of Neoadjuvant Opdivo (nivolumab) And Chemotherapy Followed by Adjuvant Opdivo For Resectable, High-Risk Non-Small Cell Lung Cancer With PD-L1 Expression ≥1%
BMYCMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up
BMYCMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.
Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit
BMYBristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial.
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
BMYLantern Pharma receives FDA clearance to begin Phase 1b/2 trial of LP-184 in advanced NSCLC patients with key mutations and low PD-L1 expression.
A Look Into Bristol-Myers Squibb Inc's Price Over Earnings
BMY2seventy Bio Announces Bristol Myers Squibb Will Acquire All Remaining Shares Not Tendered In Offer Through Second-Step Merger At Same Price In Tender Offer Of $5.00/Share
BMYWall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
BMYFDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months
BMYFDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.
MHRA Authorizes Cancer Treatment Variation With An Administration Time Of 3–5 Minutes; Approved New Under-The-Skin Injection Version Of Nivolumab (Opdivo)
BMYTop 3 Health Care Stocks That May Rocket Higher In April
BMYBristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact
BMYBristol Myers reported Q1 revenue of $11.2 billion, raised 2025 guidance, and saw strong Growth Portfolio sales offset Legacy product declines.
Bristol-Myers Squibb Raises FY2025 Adj EPS Guidance from $6.55-$6.85 to $6.70-$7.00 vs $6.74 Est; Raises FY2025 Sales Guidance from $45.50B to $45.80B-$46.80B vs $45.76B Est
BMYBristol-Myers Squibb Q1 Adj. EPS $1.80 Beats $1.49 Estimate, Sales $11.20B Beat $10.70B Estimate
BMYPepsiCo, Alphabet And 3 Stocks To Watch Heading Into Thursday
BMYDow Jumps Over 400 Points Amid China Tariff Hopes, Investor Fear Eases: Greed Index Remains In 'Fear' Zone
BMYEvotec Deepens CELMoDs Alliance With Bristol Myers Squibb As Molecular Glue Degrader Pipeline Expands
BMYCantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $55 Price Target
BMYJefferies Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $68
BMYBeyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock
BMYBristol-Myers Squibb Topline Results From Phase 3 ARISE Trial Did Not Reach Threshold For Statistical Significance For Primary Endpoint
BMYBristol Myers Squibb Releases Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy As An Adjunctive Treatment to Atypical Antipsychotics In Adults With Schizophrenia
BMYPiper Sandler Initiates Coverage On Bristol-Myers Squibb with Overweight Rating, Announces Price Target of $65
BMYCantor Fitzgerald Assumes Bristol-Myers Squibb at Neutral, Announces Price Target of $55
BMYBristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach
BMYFDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
BMYWhy Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?
BMYBristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.
Optellum Enters An Agreement With Bristol Myers Squibb To Leverage AI In Early Diagnosis And Precision Lung Cancer Care
BMYBristol Myers Squibb Says Phase 3 ODYSSEY-HCM Trial Evaluating Camzyos For Treatment Of Symptomatic NYHA Class II-III nHCM Did Not Meet Dual Primary Endpoints Of Changes From Baseline To Week 48 Compared To Placebo In KCCQ-23 CSS And pVO2
BMYFDA Approves Bristol Myers Squibb's Opdivo plus Yervoy as First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY